CSL and Alentis launch global partnership to develop lixudebart for rare kidney and liver diseases
CSL and Alentis Therapeutics have signed an exclusive worldwide collaboration to co‑develop and co‑promote lixudebart, an investigational monoclonal antibody targeting claudin‑1. CSL will make an upfront payment of US$355 million to Alentis and may pay up to US$1.2 billion in milestone fees. The companies will fund ongoing Phase 2 trials in ANCA‑associated vasculitis with rapidly progressive glomerulonephritis and plan additional Phase 2 studies in focal segmental glomerulosclerosis and primary sclerosing cholangitis, with a Phase 3 trial also slated. Once the drug reaches the market, CSL will receive 55 % of worldwide profits while Alentis will retain the remaining 45 %.
Why it matters
The agreement gives CSL a new potential asset in the nephrology and hepatology space, expanding its pipeline beyond existing products. The large upfront and milestone payments provide Alentis with significant financing to advance development. Profit‑sharing terms mean CSL will benefit from any commercial success, while Alentis retains a sizable share of future revenues.
Key facts
- 1CSL will pay Alentis an initial US$355 million. prnewswire.com
- 2Alentis may receive up to US$1.2 billion in commercial milestone payments. prnewswire.com
- 3Global profits from lixudebart will be divided 55 % to CSL and 45 % to Alentis. prnewswire.com
- 4Lixudebart is currently in a Phase 2 RENAL trial for ANCA‑associated vasculitis with rapidly progressive glomerulonephritis. prnewswire.com
- 5Planned Phase 2 trials will also evaluate lixudebart in focal segmental glomerulosclerosis and primary sclerosing cholangitis. prnewswire.com
- 6CSL will fully fund the completion of the Phase 2 RENAL trial, a planned Phase 3 trial in the same disease, and the additional Phase 2 studies. prnewswire.com
Summary written by AlphAI from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.